NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an ant
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.